Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lamivudine/Zidovudine vs Zalcitabine/Zidovudine in HIV
NCT00002436Phase 3Completed
- Sponsor
- GSK
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of lamivudine in human immunodeficiency virus infection (HIV) (3 arms), sponsored by GSK. Primary endpoints: Safety and Efficacy. Status: completed.
02
Drugs
lamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00002436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002436.